spacer
home > ebr > spring 2018 > redefining proteomics
PUBLICATIONS
European Biopharmaceutical Review

Redefining Proteomics

Tumour suppressor p53 (TP53) is a gene, not a protein. It is rhetorically convenient but scientifically inaccurate to suggest these are morphological variants of the same thing. Human cells splice and assemble in at least nine different ways the exons present in the TP53 gene. Therefore, TP53 isoform 7 is the appropriate name for an mRNA intermediary between gene and protein. Likewise, protein does not simply swap ribonucleotides for amino acids at a 3:1 ratio.

Many residues will be variously and reversibly modified with chemical, carbohydrate, lipidatious, and/or proteinacious adducts that will impart different structures and biochemical properties; direct the protein to different locations; alter activities, functions, and interactions; and control destruction of the molecule itself – all as the larger cell sees fit. These co- and post-translational modifications (PTM) are essential to everything about proteins that makes them so. Methylated, phospho-TP53 isoform 7 is thus a protein. If a proteomic screen is not providing this level of information, is it technically even proteomic?

Mass Spectrometry: Necessary but Insufficient

Stable proteins may have no concurrently existing, corresponding mRNA. Post-transcriptional regulation means not all mRNA present within cells has such corresponding protein. To identify the protein components of a complex sample, no substitute for mass spectrometry (MS) exists, particularly in targeted approaches where one seeks to identify the presence of a particular component within complex mixtures

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Christian Loch is Chief Executive and Science Officer at AVMBioMed. He is also adjunct faculty in the Department of Chemistry at Villanova University, US, where he teaches proteomics in the graduate school. Christian has 10 years of industry experience and holds an MPH in epidemiology from the University of Washington, US, and a PhD in biochemistry from the University of Virginia, US.
spacer
Dr Christian Loch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement